Navigation Links
BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies
Date:3/9/2011

CARY, N.C., March 9, 2011 /PRNewswire/ -- iAdvantage Software, Inc., a leading solutions provider for managing development and pre-clinical life science studies, today announced that BioTox Sciences (BTS), a GLP Contract Research Organization, headquartered in San Diego, California, is deploying the eStudy™ hosted solution to manage its GLP and Non-GLP preclinical/nonclinical studies.

(Logo: http://photos.prnewswire.com/prnh/20110309/CL62195LOGO)

In 2010, BioTox Sciences expanded its resources from people to facility to accommodate growing Sponsors' needs.  The final challenge was selecting a software platform that would handle the different preclinical study types BTS conduct's today, yet flexible enough to meet the ever-changing needs they may encounter as they continue to grow.

"After weighing our options and careful due diligence, BioTox Sciences chose to implement eStudy, by iAdvantage Software," commented Tareq Abu-Nadi, BioTox Sciences, Business Development/Study Director.  "eStudy will complement and streamline the study processes conducted at BTS by increasing productivity and speed of reporting while maintaining 21 CFR parts 58 and 11 compliance."

"eStudy's flexibility ensures that BTS Study Directors would be able to use eStudy on various projects and multiple species.  Whether a typical 28 day toxicity study in rats or dogs, or a long term surgery study in NHPs, eStudy will be used to manage the study, capture the data and allow for on-demand reporting of results upon Sponsor request.  This significant investment gives us the ability to produce complete study books in mere hours, and help Sponsors make key decisions on development of compounds and initiate more projects," concluded Abu-Nadi.

eStudy is a 100% web-based study management platform that iAdvantage Software hosts for BTS at Cegidem/Dendrite's world-class network operating center in Chesapeake, VA.  "eStudy will continually grow with BioTox Sciences, easily adapt to new study-types, marry to BTS' operational work-flow and interface with 3rd party instruments and tools," stated Diana Michelotti, Director of Marketing and Sales for iAdvantage.  "eStudy implemented for BTS, provides BTS with a custom fit solution without the start-from-scratch price."

About iAdvantage SoftwareiAdvantage is dedicated to empowering scientists and management in the pharmaceutical and biotechnology arenas with efficient, web-based electronic study management and reporting tools that automate cumbersome tasks and optimize time to results thereby improving productivity, real-time business intelligence and time to market.

iAdvantage products include eStudy, a truly web-based enterprise solution for study design, eNotebook design, collection of data from multiple sources, multiple users and multiple locations, integration of data in real-time to a secure storage device, maintaining data integrity (complying with 21 CFR Parts 58 and 11) with the flexibility of on-demand access, data analysis and reporting that is user-defined and user-controlled.  iAdvantage places control in the hands of the scientist and not at the mercy of rigid study management systems.

iAdvantage is headquartered in Cary, North Carolina, near the life science and biotech hub of Research Triangle Park.  More than 140 life science companies in North America and Europe use iAdvantage products in their research and development.  Please visit www.iadvantagesoftware.com for more information.

About BioTox SciencesBioTox Sciences, San Diego, CA, is a leading Contract Research Organization (CRO) offering comprehensive services for nonclinical and preclinical studies operates a state of the art 20,000 sqf AAALAC accredited vivarium.  BioTox Sciences services encompass toxicology, pharmacology, metabolism, disease models, surgery models, behavior and safety testing, PK/PD and other customized testing in support of nonclinical drug development for pharmaceutical, biotechnology and medical device companies.  Visit www.biotoxsciences.com/ for more information.Inquires:Diana MichelottiDirector of Marketing and SalesiAdvantage Software, Inc. - 919-469-3888 ext. 121dmichelotti@iadvantagesoftware.comTareq Abu-NadiBusiness Development/Study DirectorBioTox Sciences - 858-605-5882 ext. 302tabunadi@biotoxsciences.com
'/>"/>

SOURCE iAdvantage Software, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
3. RBC Life Sciences Reports Sales and Earnings Growth in 2010
4. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
5. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
6. Novavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries
7. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
8. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
9. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
10. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
11. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Fourth-quarter 2016 revenues of $1,242 million brings ... of guidance Company reports ... associated with the write-down of goodwill and intangible assets ... Fourth-quarter reported $14.96 diluted (GAAP) ... $14.48 diluted (GAAP) loss per share from continuing operations ...
(Date:2/27/2017)... Halyard Health, Inc. (NYSE: HYH ) ... its 2017 outlook and related key planning assumptions. Executive Summary ... a 2 percent increase compared to the prior year. ... $10 million compared to net income of $15 million in ... was $24 million compared to adjusted net income of $27 ...
(Date:2/27/2017)... 27, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), ... molecular diagnostic tests and pathology services, announced today the ... upcoming United States and Canadian ... 2017 in San Antonio, Texas . ... data from the Company,s extensive experience in molecular thyroid ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 2017 , ... Much attention has been paid to the problem of men ... painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain medications ... in male populations.(1) , The proportion of women using illicit drugs is also increasing ...
(Date:2/27/2017)... ... ... Orange County dentist, Dr. A. Rassouli, comments on the new ... bacteria in plaque infect the gums and other tissues supporting the teeth. Treatment typically ... SRP, and can include surgical therapies if the condition has led to significant damage. ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon ... proud to announce a new informational post on robotic hair transplantation. San Francisco ... (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
Breaking Medicine News(10 mins):